Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.

Abstract

BACKGROUND:

Bone metabolism is a dynamic process that is influenced by food ingestion. Endogenous incretins have been shown to be important regulators of bone turnover. The aim of the present study was to assess whether a dipeptidylpeptidase (DPP)-4 inhibitor affects markers of bone resorption and calcium homeostasis.

METHODS:

The present study was a single-center, double blind, randomized clinical trail. Fifty-nine drug-naïve patients with type 2 diabetes (T2D) were randomized to either 1 year treatment with the DPP-4 inhibitor vildagliptin (100 mg, once daily; n = 29) or placebo (n = 30). Patients received a standardized breakfast after measurement of serum concentrations of cross-linked C-terminal telopeptide (s-CTx), a bone resorption marker influenced by food intake, before and after 50 weeks treatment.

RESULTS:

Vildagliptin did not change postprandial s-CTx concentrations compared with pretreatment levels (between-group ratio 1.15 ± 0.17; P = 0.320). Fasting serum alkaline phosphatase, calcium, and phosphate were also unaffected y 1 year treatment with vildagliptin.

CONCLUSIONS:

Treatment with vildagliptin for 1 year was not associated with changes in markers of bone resorption and calcium homeostasis in drug-naïve patients with T2D and mild hyperglycemia.

• Authors: Mathijs C Bunck, Marieke Poelma, E Marelise Eekhoff, Anja Schweizer, Robert J Heine, Giel Nijpels, James E Foley, Michaela Diamant
• Journal: Journal of diabetes (J Diabetes) Vol. 4 Issue 2 Pg. 181-5 (Jun 2012) ISSN: 1753-0407 [Electronic] Australia
• PMID: 22051153 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2011 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.

Chemical References

• Biomarkers
• Blood Glucose
• Collagen Type I
• Dipeptidyl-Peptidase IV Inhibitors
• Insulin
• Nitriles
• Peptides
• Phosphates
• Pyrrolidines
• collagen type I trimeric cross-linked peptide
• Glucagon-Like Peptide 1
• Alkaline Phosphatase
• Vildagliptin
• Adamantane
• Calcium

Topics

• Adamantane (adverse effects, analogs & derivatives, therapeutic use)
• Aged
• Alkaline Phosphatase (blood)
• Biomarkers (blood)
• Blood Glucose (drug effects, metabolism)
• Bone Resorption (blood, metabolism)
• Bone and Bones (drug effects, metabolism)
• Calcium (blood, metabolism)
• Collagen Type I (blood)
• Diabetes Mellitus, Type 2 (blood, diagnosis, drug therapy)
• Dipeptidyl-Peptidase IV Inhibitors (adverse effects, therapeutic use)
• Double-Blind Method
• Female
• Glucagon-Like Peptide 1 (blood)
• Homeostasis
• Humans
• Insulin (blood)
• Male
• Middle Aged
• Netherlands
• Nitriles (adverse effects, therapeutic use)
• Peptides (blood)
• Phosphates (blood)
• Postprandial Period
• Pyrrolidines (adverse effects, therapeutic use)
• Time Factors
• Treatment Outcome
• Vildagliptin